NCT05779163View on ClinicalTrials.gov

A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

468

Participants

Timeline

Start Date

April 14, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Advanced Malignant Tumors
Interventions
DRUG

LBL-033 for Injection

Initial dose - MTD; Q2W; intravenous infusion

Trial Locations (6)

110801

RECRUITING

Liaoning Cancer Hospital & Institute, Shenyang

200011

RECRUITING

Obstetrics & Gynecology Hospital of Fudan University, Shanghai

350014

RECRUITING

Fujian Cancer Hospital, Fuzhou

450003

RECRUITING

Henan Cancer Hospital, Zhengzhou

510062

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

610044

RECRUITING

West China Second University Hospital,Sichuan University, Chengdu

All Listed Sponsors
lead

Nanjing Leads Biolabs Co.,Ltd

INDUSTRY